Project Grant R21AI180611
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $490K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award of $258,990.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research conducted by The Children's Hospital Corporation (doing business as Boston Children's Hospital) to examine the role of the Candida albicans TOR1 kinase and its N-terminal heat repeats in enabling this fungal pathogen to withstand oxidative stress from the host...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $265,650 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, to study the effects of antifungal drug treatment and immune dysfunction on the evolutionary dynamics of the gut-colonizing fungus Candida glabrata. This research aims to provide insights into the population dynamics and drug...
- The Project Grant award of $170,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is focused on the "Structure-Based Design of Antifungal Inhibitors Targeting the Glycosylphosphatidylinositol (GPI) Ethanolamine Phosphate Transferase, MCD4". The research aims to develop new antifungal agents with novel mechanisms of action to address emerging fungal pathogens and growing...
- The federal Project Grant award of $299,697 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel broad-spectrum antifungal agent targeting cell wall biosynthesis. The goal is to create a mechanistically unique inhibitor of the enzyme 1-3-D-glucan synthase (GS) that demonstrates potent and wide-ranging fungicidal activity, including against echinocandin-resistant...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $470,028 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to New York University (NYU) to conduct research on deciphering fungal pathogen-specific cell cycle mechanisms in order to fuel antifungal drug discovery. The 5-year grant, with a period of performance from August 21, 2025 to July 31, 2030, will focus on investigating two promising fungal cell cycle variations in the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- This $262,665 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to determine the genetic mechanisms underlying skin colonization by the emerging fungal pathogen Candida auris. The project aims to leverage the research team's molecular genetic tools and established in vitro and in vivo models to investigate clade-specific genetic circuitry that...
- This $838,320 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant will fund research to investigate fungal pathogenicity determinants and their relationship to emerging cancer therapies that can lead to increased risk of invasive fungal infections. Specifically, the research aims to understand the mechanism by which inhibition of the Bruton's...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $197,240 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the mechanisms by which fungal extracellular vesicles activate the innate immune system's interferon signaling pathways. The research aims to elucidate the role of the STING pathway in...